Biotech News

ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September

ProMIS Neurosciences (PMN)ProMIS NeurosciencesClinical readout

ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming September 2026 conferences and key investor events, and will be available for one-on-one meetings.

Conference details below:

September 9-11: Cantor Global Healthcare Conference Location: New York, NY Fireside Chat: Wednesday, September 9, 9:10-9:40 a.m. ET Participants: Pete Stavropoulos, Cantor analyst, and Neil Warma, ProMIS President & Chief Executive Officer Webcast link: Click Here

September 9-10: Moody Capital Disruptive Growth & Life Sciences Conference Location: New York, NY Presentation: Thursday, September 10, 1:45-2:05 p.m. ET, Room 1 Webcast link: Click Here

September 14-16: H.C. Wainwright 28 th Annual Global Investment Conference Location: New York, NY Presentation: Tuesday, September 15, 10:30-11:00 a.m. ET, Louis Room (4 th floor) Webcast link: Click Here

September 21 (World Alzheimer’s Day): ProMIS Neurosciences and Nasdaq mark World Alzheimer’s Day at the Nasdaq Tower Location: Nasdaq Tower, New York, NY

September 29: Roth Healthcare Opportunities Conference Location: New York, NY

During these conferences, Neil Warma, President & Chief Executive Officer of ProMIS Neurosciences, Dr. Larry Altstiel, Chief Medical Officer, and Carie Pierce, VP, Investor Relations & External Affairs, will discuss the Company’s EpiSelect™ platform, its differentiated approach to developing therapeutics for neurodegenerative diseases driven by toxic misfolded proteins, and PMN310, the Company’s lead candidate in the ongoing PRECISE-AD Phase 1b trial in early Alzheimer’s disease.

ProMIS reported blinded 6-month interim data from its fully enrolled PRECISE-AD Phase 1b trial in patients with early AD in July 2026, with 12-month topline data anticipated in early 2027.

Webcast replays of the upcoming presentations, as well as a replay of the interim data webinar, will be available in the Investors section of the website.

Click Here About ProMIS Neurosciences Inc. ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).

Investor Relations Contact: Carie Pierce, VP, Investor Relations & External Affairs

[email protected]

Related news

PMNProMIS Neurosciences2026-10-06 11:05 EST

ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer

XENEXenon2026-10-29 12:30 EST

Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain

JNJJohnson & Johnson2026-10-25 14:24 EST

Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer

JNJJohnson & Johnson2026-10-24 13:01 EST

Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk localised or locally advanced prostate cancer

ABOSAcumen Pharmaceuticals2026-10-22 11:30 EST

Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

TEVATeva Pharmaceutical Industries2026-09-18 20:30 EST

Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults

ANVSAnnovis Bio2026-11-17 13:00 EST

Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study

ANVSAnnovis Bio2026-11-12 13:00 EST

Annovis Bio Granted U.S. Patent Covering New Crystalline Form of Buntanetap

TEVATeva Pharmaceutical Industries2026-11-02 13:00 EST

Teva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-‘286) Following Interim Futility Analysis

ABOSAcumen Pharmaceuticals2026-10-30 11:00 EST

Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint

ProMIS Neurosciences

Misfolded Protein Therapeutics ProMIS Neurosciences develops antibodies that selectively recognize toxic misfolded protein species implicated in neurodegenerative disease. PMN310 PMN310 targets toxic amyloid-beta oligomers while seeking to avoid binding monomers and plaque, potentially reducing off-target immune effects. PRECISE-AD The...

Recent company news

Stock data

Close
3.21 USD
Market cap
91.02M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States